METAGENOMI THERAPEUTICS INC

MGXNASDAQ

🏆 #4518 by market capEarnings Nov 9US Equity

$1.14▼ $0.01 (−0.87%)

After hours · at close

🔔

Track MGX

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.9%

7d▲ 0.0%

14d▼ 2.6%

30d▼ 5.4%

ytd▼ 30.2%

1y▼ 50.7%

🏦Market Cap

$43M

Small Cap

📈Revenue Growth (YoY)

-50.7%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

1.9x

Cheap

Otter Score

Good

Trading Snapshot

Day Range: $1.12 – $1.15
52-Week Range: $1.07 – $3.95
Volume: $2.61B
Avg Volume: $3.26B
Shares Outstanding: 37.6M
Next Earnings: Nov 8, 2026

Fundamentals Snapshot

Annual Revenue: $25M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: 1.9x
EPS (TTM): $-2.30
Dividend Yield: —
Dilution (1yr): +1.4%

Why Investors Own MGX

✓High-growth profile — revenue up +25.2% YoY with expanding US Equity exposure.
✓Healthy economics — 66% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

METAGENOMI THERAPEUTICS INC

MGX

Financial Trends

Revenue

$25M▼ −51.8% YoY

Gross Margin

78.9%▼ −21.1% YoY

Operating Income

−$96M▲ +8.0% YoY

Free Cash Flow

−$89M▼ −20.3% YoY

Shares Outstanding

37.6M▲ +1.4% YoY

Net Cash

$1M▲ +$19M YoY

StockOtter · stockotter.space

About METAGENOMI THERAPEUTICS INC

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

🦦